Abstract
LY146032, an acidic lipopeptide antibiotic which inhibits the biosynthesis of cell wall peptidoglycan, was found to be effective in delaying death in a hamster model of pseudomembranous colitis. A dose of 0.05 mg/day was effective. The equivalent protection with vancomycin required a dose 100-fold higher, i.e., 5 mg/day.
MeSH Terms
Animals
Anti-Bacterial Agents/therapeutic use
Clindamycin/adverse effects
Cricetinae
Daptomycin
Disease Models, Animal
Enterocolitis, Pseudomembranous/drug therapy
Male
Mesocricetus
Peptides/therapeutic use
Vancomycin/therapeutic use
Chemicals
Anti-Bacterial Agents
Peptides
Clindamycin
Vancomycin
Daptomycin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Dong M Y
Department of Community Health, Tufts University School of Medicine, Boston, Massachusetts 02111.
Chang T W
Gorbach S L
References (4)
4 references, click to expand
-
The protective effect of vancomycin on clindamycin-induced colitis in hamsters.
Johns Hopkins Med J. 1977 Oct;141(4):183-92
PMID: 909214
-
Effect of calcium on in vitro activity of LY146032 against Clostridium difficile.
Antimicrob Agents Chemother. 1987 Mar;31(3):461-2
PMID: 3034146
-
Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins.
Infect Immun. 1978 Nov;22(2):418-22
PMID: 730363
-
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters.
J Infect Dis. 1977 Nov;136(5):701-5
PMID: 915343